$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000117887920000035 Filed on November 05, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$70.57M	$67.44M	$48.77M
YoY Change	27.63%	38.28%	136.78%
Cost Of Revenue	$9.420M	$8.399M	$5.596M
YoY Change	35.54%	50.09%	29.84%
Gross Profit	$61.15M	$59.04M	$43.17M
YoY Change	26.47%	36.75%	165.09%
Gross Profit Margin	86.65%	87.55%	88.53%
Selling, General & Admin	$43.69M	$37.85M	$39.68M
YoY Change	0.9%	-4.61%	24.52%
% of Gross Profit	71.45%	64.11%	91.91%
Research & Development	$79.29M	$70.42M	$58.89M
YoY Change	-13.73%	19.57%	-57.39%
% of Gross Profit	129.66%	119.28%	136.41%
Depreciation & Amortization	$2.550M	$2.496M	$1.116M
YoY Change	67.76%	123.66%	4.01%
% of Gross Profit	4.17%	4.23%	2.59%
Operating Expenses	$126.0M	$111.8M	$100.5M
YoY Change	-8.28%	11.27%	-41.74%
Operating Profit	-$64.84M	-$52.76M	-$57.31M
YoY Change	-27.16%	-7.93%	-63.31%
Interest Expense	-$7.950M	$6.784M	$4.026M
YoY Change	426.49%	68.5%	-14.61%
% of Operating Profit
Other Income/Expense, Net	-$810.0K	$3.019M	-$3.481M
YoY Change	-224.62%	-186.73%	235.03%
Pretax Income	-$73.59M	-$63.28M	-$62.06M
YoY Change	-18.13%	1.97%	-61.02%
Income Tax	-$2.190M	$727.0K	-$251.0K
% Of Pretax Income
Net Earnings	-$71.40M	-$64.01M	-$61.81M
YoY Change	-20.43%	3.56%	-61.17%
Net Earnings / Revenue	-101.18%	-94.92%	-126.74%
Basic Earnings Per Share		-$0.25
Diluted Earnings Per Share	-$273.4K	-$0.25	-$242.7K
COMMON SHARES
Basic Shares Outstanding	260.6M shares	259.2M shares	254.6M shares
Diluted Shares Outstanding		259.2M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$483.3M	$509.1M	$514.2M
YoY Change	6.76%	-0.99%	-8.89%
Cash & Equivalents	$163.2M	$210.6M	$166.3M
Short-Term Investments	$320.0M	$298.5M	$347.9M
Other Short-Term Assets	$29.70M	$15.60M	$19.60M
YoY Change	48.5%	-20.41%	20.99%
Inventory	$19.56M	$15.77M	$9.154M
Prepaid Expenses
Receivables	$46.92M	$44.83M	$33.73M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$579.5M	$585.3M	$576.7M
YoY Change	11.42%	1.49%	-4.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$43.86M	$44.62M	$34.67M
YoY Change	-8.05%	28.68%	225.29%
Goodwill	$197.8M	$197.8M	$197.8M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$23.00M	$23.00M	$23.00M
YoY Change	0.0%	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$19.10M	$26.45M	$14.35M
YoY Change	-32.57%	84.33%	135.3%
Total Long-Term Assets	$307.1M	$315.3M	$305.6M
YoY Change	-6.99%	3.15%	28.66%
TOTAL ASSETS
Total Short-Term Assets	$579.5M	$585.3M	$576.7M
Total Long-Term Assets	$307.1M	$315.3M	$305.6M
Total Assets	$886.5M	$900.5M	$882.3M
YoY Change	4.27%	2.07%	5.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.06M	$14.76M	$81.50M
YoY Change	-21.45%	-81.88%	50.09%
Accrued Expenses	$103.7M	$97.00M	$6.400M
YoY Change	1340.28%	1415.63%
Deferred Revenue	$0.00
YoY Change	-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$129.7M	$111.7M	$93.08M
YoY Change	0.67%	20.03%	41.29%
LONG-TERM LIABILITIES
Long-Term Debt	$389.3M	$388.6M	$149.3M
YoY Change	160.4%	160.28%	-53.17%
Other Long-Term Liabilities	$6.379M	$4.817M	$4.591M
YoY Change	20.45%	4.92%	51.57%
Total Long-Term Liabilities	$6.379M	$4.817M	$4.591M
YoY Change	20.45%	4.92%	51.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$129.7M	$111.7M	$93.08M
Total Long-Term Liabilities	$6.379M	$4.817M	$4.591M
Total Liabilities	$600.1M	$580.3M	$334.0M
YoY Change	60.56%	73.72%	-21.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.045B	-$2.000B	-$1.700B
YoY Change	15.65%	17.65%	27.42%
Common Stock	$2.311B	$2.277B	$2.213B
YoY Change	3.65%	2.89%	27.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$286.4M	$320.3M	$548.3M
YoY Change
Total Liabilities & Shareholders Equity	$886.5M	$900.5M	$882.3M
YoY Change	4.27%	2.07%	5.21%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$71.40M	-$64.01M	-$61.81M
YoY Change	-20.43%	3.56%	-61.17%
Depreciation, Depletion And Amortization	$2.550M	$2.496M	$1.116M
YoY Change	67.76%	123.66%	4.01%
Cash From Operating Activities	-$49.82M	-$42.01M	-$55.55M
YoY Change	-13.87%	-24.37%	-58.16%
INVESTING ACTIVITIES
Capital Expenditures	-$1.070M	-$280.0K	-$3.980M
YoY Change	-90.2%	-92.96%	47.96%
Acquisitions
YoY Change
Other Investing Activities	-$21.71M	-$153.8M	$7.170M
YoY Change	-157.3%	-2244.63%	-93.88%
Cash From Investing Activities	-$22.78M	-$154.1M	$3.190M
YoY Change	-184.5%	-4929.47%	-97.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	21.55M	238.7M	520.0K
YoY Change	575.55%	45805.77%	-99.65%
NET CHANGE
Cash From Operating Activities	-49.82M	-42.01M	-55.55M
Cash From Investing Activities	-22.78M	-154.1M	3.190M
Cash From Financing Activities	21.55M	238.7M	520.0K
Net Change In Cash	-51.05M	42.64M	-51.84M
YoY Change	84.36%	-182.25%	-140.33%
FREE CASH FLOW
Cash From Operating Activities	-$49.82M	-$42.01M	-$55.55M
Capital Expenditures	-$1.070M	-$280.0K	-$3.980M
Free Cash Flow	-$48.75M	-$41.73M	-$51.57M
YoY Change	3.9%	-19.08%	-60.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33497
	dei	Entity Registrant Name EntityRegistrantName	Amicus Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	71-0869350
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Cedar Brook Drive,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury,
	dei	City Area Code CityAreaCode	(609)
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
	dei	Local Phone Number LocalPhoneNumber	662-2000
	dei	Trading Symbol TradingSymbol	FOLD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	260587610	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210631000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	298451000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	309903000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	44828000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33284000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	15767000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	14041000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15600000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20008000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	585277000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	520073000	USD
CY2020Q3	fold	Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases	6850000	USD
CY2019Q4	fold	Accumulated Depreciation And Amortization Finance And Operating Right Of Use Leases AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases	5342000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23397000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33315000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23582000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17604000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44618000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47705000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	197797000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	26453000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28317000	USD
CY2020Q3	us-gaap	Assets Assets	900542000	USD
CY2019Q4	us-gaap	Assets Assets	850207000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	14764000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21722000	USD
CY2020Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	89595000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	99901000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7368000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7189000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	111727000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	128812000	USD
CY2020Q3	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	8906000	USD
CY2019Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	8906000	USD
CY2020Q3	us-gaap	Long Term Debt LongTermDebt	388584000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	149505000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	16561000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22681000	USD
CY2020Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5051000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5051000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44627000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53531000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4817000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5296000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	580273000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	373782000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	259600650	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	259600650	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	255417869	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	255417869	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	2626000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2598000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2274797000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2227225000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	4576000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	2785000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-56000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	40000	USD
CY2020Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1974061000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1768610000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	320269000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	900542000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	476425000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	850207000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	67437000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	48768000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	190315000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	126944000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8399000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5596000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21627000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15018000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	59038000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	43172000	USD
	us-gaap	Gross Profit GrossProfit	168688000	USD
	us-gaap	Gross Profit GrossProfit	111926000	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	70419000	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	58892000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	229150000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	194466000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37850000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39680000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	112722000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	126561000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1034000	USD
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-789000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2680000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2652000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2496000	USD
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1116000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6299000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3261000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	111799000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	100477000	USD
	us-gaap	Operating Expenses OperatingExpenses	350851000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-64011000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-61809000	USD
	us-gaap	Operating Expenses OperatingExpenses	326940000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-52761000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-57305000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-182163000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-215014000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	518000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2752000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2898000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7990000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	6784000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	4026000	USD
	us-gaap	Interest Expense InterestExpense	14148000	USD
	us-gaap	Interest Expense InterestExpense	15105000	USD
CY2020Q3	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	0	USD
CY2019Q3	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	0	USD
	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	0	USD
	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-40624000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7276000	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7276000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3019000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3481000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3272000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63284000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-62060000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-200660000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-266025000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	727000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-251000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4791000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	634000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-205451000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-266659000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.13
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	259161799	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	254674422	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	258091170	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	235527540	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-64011000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-61809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-205451000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-266659000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	1203000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	207000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	649000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-289000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	584000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	237000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1791000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	661000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-91000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-23000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-25000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	197000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-344000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-11000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-96000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	551000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-633000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	573000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1695000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1212000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64644000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61236000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-203756000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-265447000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	360953000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9295000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-1243000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15908000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-344000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-289000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-64011000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	320269000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	476425000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20028000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-9340000	USD
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	1964000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	36912000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-96000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1791000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-205451000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	320269000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	600058000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1048000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-446000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8843000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-11000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	584000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-61809000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	548267000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	342912000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7808000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	188994000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8714000	USD
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-2264000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	31522000	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-3001000	USD
	fold	Stock Issued During Period Value Contingent Consideration StockIssuedDuringPeriodValueContingentConsideration	9316000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	31522000	USD
	fold	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	812000	USD
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	215476000	USD
	fold	Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations	19875000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	551000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	661000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-266659000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	548267000	USD
	us-gaap	Profit Loss ProfitLoss	-205451000	USD
	us-gaap	Profit Loss ProfitLoss	-266659000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1124000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2290000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6299000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3261000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	36912000	USD
	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	0	USD
	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-40624000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	58000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7276000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2680000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2652000	USD
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	1084000	USD
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-2665000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	136000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10845000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12644000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2182000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2016000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4377000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3321000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-23424000	USD
	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-1250000	USD
	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-1500000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-183468000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-192584000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	272679000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	389242000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	261322000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	311965000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2160000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9087000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9197000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	68190000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	188994000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	155249000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	385929000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	213425000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	169701000	USD
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	470000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	177000	USD
	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	9340000	USD
	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	3001000	USD
	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	0	USD
	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	19875000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20028000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7808000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	812000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	241310000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	214311000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2591000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	67084000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	87326000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146341000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82375000	USD
	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	9316000	USD
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	14875000	USD
	us-gaap	Interest Paid Net InterestPaidNet	16712000	USD
	us-gaap	Interest Paid Net InterestPaidNet	13145000	USD
	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	265000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2802000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2000000000.0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of September 30, 2020 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span>. The Company's accounts receivable at September 30, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers and the geographic economic environments and conditions to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	67437000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	48768000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	190315000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	126944000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210600000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	298500000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210631000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	210631000	USD
CY2020Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	508940000	USD
CY2020Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	159000	USD
CY2020Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2020Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	509082000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210631000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	210631000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	298309000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	159000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	298451000	USD
CY2020Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	508940000	USD
CY2020Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	159000	USD
CY2020Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2020Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	509082000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	142837000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	452502000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	452740000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	142837000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	309665000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	309903000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	452502000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	452740000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	9500000	USD
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2020Q1	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	117700000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	42600000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210631000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166319000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2794000	USD
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3382000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	213425000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	169701000	USD
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1012000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6544000	USD
CY2020Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8201000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3660000	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6554000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3837000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	15767000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	14041000	USD
	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	19900000	USD
CY2020Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2020Q3	us-gaap	Long Term Debt LongTermDebt	388584000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	149505000	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7300000	USD
CY2019Q3	fold	Debt Instrument Convertible Debt Exchange Agreement Aggregate Principal Amount DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount	247200000	USD
CY2019Q3	fold	Debt Instrument Convertible Debt Exchange Agreement Shares Authorized For Issuance DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance	44000000.0	shares
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	fold	Debt Instrument Convertible Debt Exchange Agreement Accrued And Unpaid Interest DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest	1300000	USD
CY2019Q3	fold	Gain Loss On Extinguishment Of Debt Additional Paid In Capital GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital	215000000.0	USD
CY2019Q3	fold	Gain Loss On Extinguishment Of Debt Fair Value Of Common Shares Issued GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued	400000	USD
	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-40600000	USD
CY2020Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6250000	USD
CY2019Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3820000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	13245000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	12779000	USD
CY2020Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	395000	USD
CY2019Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	182000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	869000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2164000	USD
CY2020Q3	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	197000	USD
CY2019Q3	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	23000	USD
	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	255000	USD
	fold	Amortization Deferred Financing Costs AmortizationDeferredFinancingCosts	145000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15908000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8843000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	36912000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31522000	USD
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	301957000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25361000	USD
CY2020Q3	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	3585000	USD
CY2020Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	28946000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	314270000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	22681000	USD
CY2019Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	4419000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	27100000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	24327000	USD
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-789000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2680000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21247000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22681000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19700000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1034000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2652000	USD
CY2020Q3	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	0	USD
CY2019Q3	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	0	USD
	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	0	USD
	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	316000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	25361000	USD
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22036000	USD
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	25361000	USD
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22036000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8800000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-64011000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-61809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-205451000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-266659000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	259161799	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	254674422	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	258091170	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	235527540	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26878000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26387000	shares

Files In Submission

Name	View Source	Status
0001178879-20-000035-index-headers.html	Edgar Link	pending
0001178879-20-000035-index.html	Edgar Link	pending
0001178879-20-000035.txt	Edgar Link	pending
0001178879-20-000035-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-09302020xex311.htm	Edgar Link	pending
fold-09302020xex312.htm	Edgar Link	pending
fold-09302020xex321.htm	Edgar Link	pending
fold-20200930.htm	Edgar Link	pending
fold-20200930.xsd	Edgar Link	pending
fold-20200930_cal.xml	Edgar Link	unprocessable
fold-20200930_def.xml	Edgar Link	unprocessable
fold-20200930_htm.xml	Edgar Link	completed
fold-20200930_lab.xml	Edgar Link	unprocessable
fold-20200930_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2020 Q4 Form 10-Q Financial Statement

#000117887920000035 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2020 Q4 Form 10-Q Financial Statement

#000117887920000035 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold